BackInnoCan Pharma Overview

InnoCan Pharma Total Liabilities

Track InnoCan Pharma's total liabilities ($2.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$2.95M
↓ 32.17% YoYΔ $-1.40M vs prior year quarter

Peer trimmed avg / median

Loading

InnoCan Pharma Total Liabilities History

Loading

InnoCan Pharma vs. peers: Total Liabilities Comparison

Loading

InnoCan Pharma Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

InnoCan Pharma (INNPF) FAQ

As of the most recent data (June 2026), INNPF shows a total liabilities of $2.9M. That compares with $4.3M in the prior-year period — down 32.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INNPF's total liabilities is now $2.9M (was $4.3M) — a 32.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether InnoCan Pharma is outperforming or lagging.

Tracking INNPF's total liabilities over time shows whether InnoCan Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $2.9M That compares with $4.3M in the prior-year period — down 32.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has InnoCan Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $2.9M) with ownership activity and broader fundamentals.